Glycaemic effects of incretins in Type 1 diabetes mellitus: A concise review, with emphasis on studies in humans

Regulatory Peptides

Volumn 128, Issue 2, 2005, Pages 149-157

  Dupre, John ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Glycaemic effects; Incretins; Type 1 diabetes mellitus

Indexed keywords

EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

DRUG MECHANISM; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRIENT; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIDE EFFECT; STOMACH EMPTYING;

EID: 15044357070     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2004.06.003     Document Type: Review

References (50)

1. J. Dupre Influences of the gut on the endocrine pancreas: an overview of established and potential physiological mechanisms in the endocrine pancreas E. Samols 1991 Raven Press New York, USA 253 281
2. C.F. Deacon What do we know about the secretion and degradation of incretin hormones? Regul. Pept. 128 1996 117 124 (this issue)
3. I.M. Hramiak, J. Dupre, M.T. Behme, D.T. Finegood, and T.J. McDonald Entero-pancreatic hormones in C-peptide positive Type 1 (TID) and lean Type 2 (T2D) diabetes mellitus The Ninth International Congress of Endocrinology, Nice, France, Proceedings 1992 P-10.03.070:369
4. W.O.C. Creutzfeldt, N. Kleine, B. Willms, C. Orskov, J.J. Holst, and M.A. Nauck Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36) amide in Type 1 diabetic patients Diabetes Care 19 6 1996 580 586
5. M. Gutniak, C. Orskov, J.J. Holst, B. Ahren, and S. Efendic Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus N. Engl. J. Med. 326 1992 1316 1322
6. A. Wettergren, B. Schjoldager, and P.E. Mortensen Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man Dig. Dis. Sci. 4 1993 665 673
7. B. Willms, J. Werner, J.J. Holst, C. Orskov, W. Creutzfeldt, and M.A. Nauck Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients J. Clin. Endocrinol. Metab. 81 1 1996 327
8. J. Dupre, M. Jenner, J.L. Mahon, C. Purdon, N.W. Rodger, and C.R. Stiller Endocrine-metabolic function in remission-phase insulin-dependent diabetes mellitus (IDDM) during administration of cyclosporin Diabetes 40 5 1991 598 604
9. S. Martin, B. Pawlowski, G. Greulich, A.G. Ziegler, T. Mandrup-Poulsen, J. Mahon For the Canadian-European Randomized Control Trial Group Natural course of remission in IDDM during 1st year after diagnosis Diabetes Care 15 1 1992 66 74
10. The Canadian-European Randomized Control Trial Group Cyclosporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion Diabetes 37 11 1988 1574 1582
11. I.M. Hramiak, J. Dupre, and D.T. Finegood Determinants of clinical remission in recent-onset insulin dependent diabetes mellitus (IDDM) Diabetes Care 16 1 1993 125 132
12. J.L. Mahon, J. Dupre, C.R. Stiller, and A.P. Donner Immuno-suppression in IDDM: rationale, risks, benefits and strategies. Editorial Diabetes Care 13 7 1990 806 809
13. J. Dupre The honeymoon period or remission phase of Type 1 diabetes mellitus S.M. Marshall P.D. Home R.A. Rizzo The diabetes annual/10 1996 Elsevier Science 149 168
14. D.K. McCulloch, D.J. Koerker, S.E. Kahn, S. Bonner-Weir, and J.P. Palmer Correlations of in vivo β-cell function tests with â-cell mass and pancreatic insulin content in streptozocin-administered baboons Diabetes 40 1991 673 679
15. B. Ahren Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice Am. J. Physiol., Regul. Integr. Comp. Physiol. 286 2004 R269 R272
16. S. Winer, H. Tsui, A. Lau, A. Song, X. Li, and R.K. Cheung Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive Nat. Med. 9 2 2003 198 205
17. A.M. Chang, G. Jakobsen, J. Sturis, M.J. Smith, C.J. Bloem, and B. An The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose Diabetes 52 2003 1786 1791
18. J. Dupre, M.T. Behme, I.M. Hramiak, P. McFarlane, M.P. Williamson, and P. Zabel Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM Diabetes 44 1995 626 630
19. E.W. Kraegen, D.J. Chisholm, and M.E. McNamara Timing of insulin delivery with meals Horm. Metab. Res. 13 1981 365 367
20. J. Dupre, M.T. Behme, I.M. Hramiak, and T.J. McDonald Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM Diabetes Care 20 3 1997 381 384
21. M.T. Behme, J. Dupre, and T.J. McDonald Glucagon-like peptide 1 improved glycaemic control in type 1 diabetes BMC Endocr. Disord. 3 2003 3
22. J.M. Egan, A.R. Clocquet, and D. Elahi The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to Type 2 diabetes JCEM 87 3 2002 1282 1290
23. J. Dupre, M.T. Behme, and T.J. McDonald Exendin-4 normalized post cibal glycemic excursions in type 1 diabetes J. Clin. Endocrinol. Metab. 2004 3469 3473
24. S. Dinneen, A. Alzaid, D. Turk, and R. Rizza Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM Diabetologia 38 1995 337 343
25. M.A. Nauck, A. El-Ouaghlidi, M. Hompesch, J. Jacobsen, and B. Elbroend No impairment of hypoglycemia counter-regulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with Type 2 diabetes. The International Diabetes Federation Abstract Volume of the 18th Congress. Paris, France. August 2003. Abstract #824 Diabetologia 46 Suppl. 2 2003 A285
26. J.C. Brown, J.R. Dryburgh, S.A. Ross, and J. Dupre Identification and actions of GIP Recent Prog. Horm. Res. 31 1975 487
27. J. Dupre, Y. Caussignac, T.J. McDonald, and S. Van Vliet Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia J. Clin. Endocrinol. Metab. 72 1 1991 125 129
28. J.J. Meier, B. Gallwitz, N. Siepmann, J.J. Holst, C.F. Deacon, and W.E. Schmidt Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia Diabetologia 46 6 2003 798 801
29. J. Schirra, P. Udert, U. Wank, P. Leicht, R. Arnold, and B. Goke Differential effects of subcutaneous GLP-1 on gastric emptying, gastroduodenal motility, and pancreatic function in men Proc. Assoc. Am. Physicians 109 1 1997 84 97
30. L.A. Slezak, and D.K. Andersen Pancreatic resection: effects on glucose metabolism World J. Surg. 25 2001 452 460
31. J. Radziuk, T.J. McDonald, D. Rubenstein, and J. Dupre Initial splanchnic extraction of ingested glucose in normal man Metabolism 27 1978 657 669
32. F.J. Service, V.J. Heiling, V.L.W. Go, and R.A. Rizza Lack of effect of gastric inhibitory polypeptide on hepatic and extrahepatic insulin action J. Clin. Endocrinol. Metab. 70 7 1990 1398 1402
33. R.P. Eaton, R.C. Allen, and D.S. Schade Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion J. Clin. Endocrinol. Metab. 56 1983 1294 1300
34. J. Dupre, M.T. Behme, I.M. Hramiak, and C.J. Longo Hepatic extraction of insulin after stimulation of secretion with oral glucose or parenteral nutrients Metabolism 42 1993 921 927
35. J.J. Meier, B. Gallwitz, N. Siepmann, J.J. Holst, C.F. Deacon, and W.E. Schmidt The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP) Regul. Pept. 113 2003 95 100
36. G.S. Meneilly, C.H. McIntosh, R.A. Pederson, J.F. Habener, M.R. Ehlers, and J.M. Egan Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes Diabetes Care 26 2003 837 842
37. G.S. Meneilly, C.H. McIntosh, R.A. Pederson, J.F. Habener, R. Gingerich, and J.M. Eganj Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes Diabetes Care 24 2001 1951 1961
38. D.A. D'Alessio, S.E. Kahn, C.R. Leusner, and J.W. Ensinck Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal J. Clin. Invest. 93 1994 2263 2266
39. J. Guan, P.F. Zucker, M.T. Behme, and J. Dupre Insulin resistance prevented by portal delivery of insulin in rats with renal subcapsular islet grafts Diabetes 46 1997 372 378
40. J.J. Holst Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes Metab. Res. Rev. 18 2002 430 441
41. I. Idris, D. Patiag, S. Gray, and R. Donnelly Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1 Biochem. Pharmacol. 63 5 2002 993 996
42. D.J. Chisholm, T.J. McDonald, J. Dupre, T. Pozefsky, and G.A. Klassen Interaction of secretin and insulin on human forearm metabolism Eur. J. Clin. Invest. 5 1975 487
43. P.E. Cryer, C. Binder, G.B. Bolli, A.D. Cherrington, E.A.M. Gale, and J.E. Gerich Hypoglycemia in IDDM Diabetes 38 1989 1193 1199
44. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N. Engl. J. Med. 329 1993 977 986
45. M. Zander, S. Madsbad, J. Lysgaard, and J.J. Holst Effect of 6-week course of glucagon-like peptide 1 on glucose control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 2002 824 830
46. A.A. Young, B.R. Gedulin, S. Bhavasar, N. Bodkin, C. Jodka, and B. Hansen Glucose-lowering and insulin-sensitizing actions of exendin-4. Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic Rhesus monkeys (Macaca mulatta) Diabetes 48 1999 1026 1034
47. C.M. Edwards, S.A. Stanley, R. Davis, A.E. Brynes, G.W. Frost, and L.J. Seal Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am. J. Physiol., Endocrinol. Metab. 281 2001 E155 E161
48. R.L. Batterham, C.W. LeRoux, M.A. Cohen, A.J. Park, S.M. Ellis, and M. Patterson Pancreatic polypeptide reduces appetite and food intake in humans J. Clin. Endocrinol. Metab. 88 2003 3989 3992
49. K. Wynne, S. Stanley, and S. Bloom The gut and regulation of body weight J. Clin. Endocrinol. Metab. 89 6 2004 2576 2582
50. E.J. Abraham, C.A. Leech, J.C. Lin, H. Zulewski, and J.F. Habener Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells Endocrinology 143 8 2002 3152 3161